Waters Corp to Acquire BD's Biosciences and Diagnostic Solutions Business in $17.5B Reverse Morris Trust

summarizeSummary

Waters Corporation announced a definitive agreement to acquire Becton, Dickinson and Company's Biosciences and Diagnostic Solutions business for approximately $17.5 billion through a tax-efficient Reverse Morris Trust transaction, significantly expanding its market and product portfolio.

check_boxKey Events

• Acquisition Details

  Waters will acquire BD's Biosciences and Diagnostic Solutions (BDS) business, valued at approximately $17.5 billion, via a Reverse Morris Trust transaction. The merger is expected to close around the end of the first quarter of calendar year 2026.

• Ownership Structure

  Existing Waters shareholders are expected to own approximately 60.8% of the combined company, with former BD shareholders owning approximately 39.2%.

• Strategic Rationale

  The acquisition is expected to double Waters' accessible market to $40 billion, accelerate growth in high-potential adjacencies, and deliver $345 million in annualized Adjusted EBITDA synergies by year five.

• Financing & Debt

  SpinCo (BDS business) will incur up to $4.0 billion in new debt, which Waters will guarantee post-merger. The combined company's gross debt is anticipated to be approximately 2.6x EBITDA.

auto_awesomeAnalysis

This is a highly significant and transformational acquisition for Waters, substantially expanding its market presence and product offerings in life sciences tools and diagnostics. The $17.5 billion valuation of the BDS business represents a material portion of Waters' current market capitalization, indicating a major strategic shift. While the transaction involves significant dilution for existing Waters shareholders and the assumption of substantial debt, the strategic benefits, including doubling the accessible market, accelerating growth in key adjacencies, and realizing $345 million in expected synergies, are compelling. The unanimous board approval underscores confidence in the long-term value creation potential. Investors should monitor the integration process and the realization of anticipated synergies, as well as the combined company's debt management post-closing.